Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective.
anti-doping
athlete biological passport 2
cbc
growth hormone
steroidomics
trend analysis
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
03
2021
accepted:
20
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Growth Hormone (GH) under its human recombinant homologue (rhGH), may be abused by athletes to take advantage of its well-known anabolic and lipolytic properties; hence it is prohibited in sports by the World Anti-Doping Agency. Due to the rapid turnover of rhGH, anti-doping screening tests have turned to monitor two endocrine biomarkers (IGF-I and P-III-NP), but unfortunately, they show population-wise variability, limiting the identification rate of rhGH users. Previous studies have evidenced the numerous effects of GH on human physiology, especially in hematopoiesis and steroidogenesis. In this work, aiming to discover novel physiological rhGH biomarkers, we analyzed the complete blood count and the steroidomics profile of healthy, physically active, young males treated either with EPO + rhGH or EPO + placebo. The time-trends of these two physiological routes have been analyzed through geometric trajectory analysis (GTA) and OPLS-DA. Individuals supplemented with micro-doses of rhGH exhibited different leukopoietic and steroidal profiles compared to the control population, suggesting a role of the rhGH in both pathways. In the article, hypotheses on the observed differences are discussed according to the most recent literature and compared to results in animal models. The use of leukopoietic and steroidal biomarkers together with endocrine biomarkers (IGF-1 and P-III-NP) allows to correctly classify over 98% of samples with no false positives, miss-classifying only one single sample (false negative) over a total of 56; a promising result, if compared to the current rhGH detection strategies.
Identifiants
pubmed: 34179089
doi: 10.3389/fmolb.2021.683675
pii: 683675
pmc: PMC8222787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
683675Informations de copyright
Copyright © 2021 Narduzzi, Buisson, Morvan, Marchand, Audran, Le Bouc, Varlet-Marie, Ericsson, Le Bizec and Dervilly.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2017 Aug 30;7(1):10039
pubmed: 28855568
Drug Test Anal. 2019 Nov;11(11-12):1698-1713
pubmed: 31301268
J Clin Invest. 1964 Jun;43:1056-65
pubmed: 14171782
Anal Chem. 2005 Oct 15;77(20):6729-36
pubmed: 16223263
Analyst. 2008 Feb;133(2):270-6
pubmed: 18227952
J Nutr. 2006 Jan;136(1 Suppl):212S-7S
pubmed: 16365085
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S18-22
pubmed: 24251151
Clin Proteomics. 2017 Jun 29;14:24
pubmed: 28670222
J Clin Endocrinol Metab. 2001 Apr;86(4):1731-7
pubmed: 11297610
PLoS Biol. 2019 Feb 14;17(2):e3000002
pubmed: 30763313
Endocr Rev. 2004 Oct;25(5):693-721
pubmed: 15466938
J Dairy Sci. 1991 May;74(5):1589-98
pubmed: 1880268
Stem Cells. 2005 Sep;23(8):1170-9
pubmed: 15955828
Chem Res Toxicol. 2004 May;17(5):579-87
pubmed: 15144214
Eur J Endocrinol. 2012 May;166(5):811-9
pubmed: 22408123
J Clin Endocrinol Metab. 2002 Dec;87(12):5668-74
pubmed: 12466370
Anal Chim Acta. 2011 Aug 26;700(1-2):189-93
pubmed: 21742132
J Clin Invest. 1994 Jul;94(1):34-43
pubmed: 7518834
Horm Res Paediatr. 2018;90(2):102-108
pubmed: 30130795
Growth Horm IGF Res. 2009 Jun;19(3):187-97
pubmed: 19144554
Drug Test Anal. 2020 Jun;12(6):711-719
pubmed: 32115881
BMC Med Res Methodol. 2016 Oct 28;16(1):147
pubmed: 27793179
Clin Endocrinol (Oxf). 2006 Oct;65(4):413-22
pubmed: 16984231
Growth Horm IGF Res. 2007 Jun;17(3):220-6
pubmed: 17339122
Drug Test Anal. 2017 Jan;9(1):30-37
pubmed: 26888146
Steroids. 2019 Jan;141:96-103
pubmed: 30529237
Lancet. 1964 Aug 22;2(7356):378-82
pubmed: 14173625
Growth Horm IGF Res. 2009 Apr;19(2):146-55
pubmed: 18812263
Bioanalysis. 2020 Jun;12(11):719-722
pubmed: 32530290
J Pediatr Endocrinol Metab. 1998 Nov-Dec;11(6):677-85
pubmed: 9829220
Drug Test Anal. 2020 Jun;12(6):677-690
pubmed: 32144900
J Reprod Immunol. 1998 Aug;39(1-2):13-9
pubmed: 9786450
Curr Opin Gastroenterol. 2012 Mar;28(2):89-98
pubmed: 22241077
Clin Endocrinol (Oxf). 1997 Jul;47(1):29-36
pubmed: 9302369
Andrology. 2013 Jul;1(4):595-601
pubmed: 23785020
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Drug Test Anal. 2019 Mar;11(3):411-421
pubmed: 30223291
Metabolites. 2019 Nov 27;9(12):
pubmed: 31783638
BMC Res Notes. 2018 Sep 5;11(1):650
pubmed: 30185229
Nat Rev Endocrinol. 2013 Jun;9(6):366-376
pubmed: 23591370
Proteomics. 2011 Sep;11(17):3565-71
pubmed: 21751372
Bioanalysis. 2012 Jul;4(13):1645-52
pubmed: 22831480
Drug Test Anal. 2020 Jul;12(7):887-899
pubmed: 32246894
Endocrinol Metab Clin North Am. 2010 Mar;39(1):59-73, viii-ix
pubmed: 20122450
Endocr Rev. 1995 Feb;16(1):3-34
pubmed: 7758431
Anal Bioanal Chem. 2018 Jan;410(1):259-275
pubmed: 29147745
Endocr Rev. 1998 Dec;19(6):717-97
pubmed: 9861545
Growth Horm IGF Res. 2007 Oct;17(5):416-23
pubmed: 17584513
Br J Pharmacol. 2008 Jun;154(3):557-68
pubmed: 18500379
Drug Test Anal. 2015 Sep;7(9):745-55
pubmed: 25645199
Endocr Connect. 2018 Jun;7(6):R212-R222
pubmed: 29724795
Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:490-5
pubmed: 16444180
Drug Test Anal. 2018 Nov;10(11-12):1744-1754
pubmed: 30315670
Growth Horm IGF Res. 2009 Aug;19(4):399-407
pubmed: 19501004